Decheng Capital LLC
Q3 2025 13F Holdings
- Locationmenlo park, CA
- Num holdings
23
- Value ($000)
$573,196
- Date Filed11/14/2025
- Form type13F-HR
- CIK0002010850
- All SEC filings
- NoteHoldings aggregated across “other managers” listed in original SEC filing, see here for detailed holdings broken out by other managers
Compare Q3 2025 toSelect Quarter
Issuer Name | Class | CUSIP | VALUE | % | Shares | Principal | Option Type |
|---|---|---|---|---|---|---|---|
CGON CG ONCOLOGY INC | COM | 156944100 | $256.65 M | 45 % | 6,371,669 | ||
NUVB Nuvation Bio Inc. | COM | 67080N101 | $96.03 M | 17 % | 25,954,439 | ||
Upstream Bio Inc. | COM | 91678A107 | $61.80 M | 11 % | 3,285,293 | ||
AARDVARK THERAPEUTICS INC | COM | 002942100 | $52.06 M | 9 % | 3,917,299 | ||
NEWAMSTERDAM PHARMA CO NV | COM | N62509109 | $18.69 M | 3 % | 657,051 | ||
MERUS NV | COM | N5749R100 | $17.56 M | 3 % | 186,546 | ||
RVMD REVOLUTION MEDICINES INC(NSM) | COM | 76155X100 | $9.81 M | 2 % | 210,000 | ||
LYEL Lyell Immunopharma, Inc. | COM | 55083R104 | $9.67 M | 2 % | 595,466 | ||
BeyondSpring Inc. | SHS | G10830100 | $7.76 M | 1 % | 4,286,104 | ||
ACRS Aclaris Therapeutics, Inc. | COM | 00461U105 | $7.68 M | 1 % | 4,041,736 |
Rows Per Page
10
- 10
- 50
- 100